STAT

Opinion: ‘Benign sexism’ intrudes at a meeting of the world’s brightest minds

Even in the wake of the #MeToo moment, we still find ourselves confronting sexism in what we perceive to be the most progressive, sophisticated spaces.

It’s 2018. We’re in the wake of the #MeToo moment. Increased reporting is exposing rampant sexism in medicine, media, and beyond. Women are now more empowered than ever to speak up in response to bias and harassment. One could think we’ve come a long way.

And yet, for all our expressed outrage at widespread sexual harassment and our newfound “wokeness” about gender equity, we still find ourselves confronting sexism in what we perceive to be the most progressive, sophisticated spaces.

That was driven home where two of us (E.M. and N.N.) were honored to be part of a panel discussing the growing epidemic of clinician burnout in the United

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

Related Books & Audiobooks